News

Filter

Current filters:

Dihydroergotamine

1 to 9 of 17 results

MAP Pharma closes $50M financing

02-04-2007

MAP Pharmaceuticals, a privately-held US biopharmaceutical firm focused on developing novel treatments…

BudesonideD. H. E. 45DihydroergotamineEntocort ECPulmicort TurbuhalerRhinocort Aqua

MAP's Tempo migraine drug sees strong Ph II data

12-03-2007

The USA's MAP Pharmaceuticals says that its candidate migraine treatment met its primary endpoints in…

D. H. E. 45Dihydroergotamine

FDA rejects Pozen's lead migraine product

27-10-2003

USA-based Pozen has revealed that it has received a non-approvableletter from the US Food and Drug Administration…

AnaproxAnaprox DSD. H. E. 45DihydroergotamineGlaxoSmithKlineGSKImitrexMetoclopramideNaprelanNaprosynNaproxenNaproxen SodiumNystatinOralReglanSumatriptan Succinate

Britannia and Novartis collaborate on DHE migraine treatment

29-09-2003

Britannia Pharmaceuticals and the UK subsidiary of Novartis have signed an agreement to accelerate the…

Britannia PharmaceuticalsD. H. E. 45DihydroergotamineNovartis

Pozen gets OK for rapid migraine drug dev't

12-08-2002

US pharmaceutical development company Pozen has had a lift in its effortto secure approval for MT 400,…

Amino AcidsAnaproxAnaprox DSD. H. E. 45DihydroergotamineInjectionMetoclopramideNaprosynNaproxenPhysostigmine SalicylateReglan

Xcel leverages neurology presence with double purchase

15-07-2002

USA-based Xcel Pharmaceuticals has acquired exclusive product rights inthe USA for Migranal (dihydrergotamine…

Amino AcidsD. H. E. 45DihydroergotamineDihydroergotamine Mesylate SprayFlunisolideInjectionMigranalMometasone FuroateNasal SprayNovartisPhysostigmine Salicylate

BPD/Inhale and Sheffield to work on migraine drug

06-05-2002

Bradford Particle Design, a wholly-owned subsidiary of InhaleTherapeutic Systems, has entered into a…

D. H. E. 45DihydroergotamineSheffield

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top